Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-0215-302 extension trial of navenibart in hereditary angioedema
ISRCTN10574179Phase 3Recruiting
- Sponsor
- Astria Therapeutics
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label trial of navenibart in hereditary angioedema (HAE), sponsored by Astria Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events. Started Feb 2026; status: recruiting.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on ISRCTN10574179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10574179.